222 related articles for article (PubMed ID: 17220732)
1. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan).
Khurana A; Runge VM; Narayanan M; Greene JF; Nickel AE
Invest Radiol; 2007 Feb; 42(2):139-45. PubMed ID: 17220732
[TBL] [Abstract][Full Text] [Related]
2. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis.
Abraham JL; Thakral C; Skov L; Rossen K; Marckmann P
Br J Dermatol; 2008 Feb; 158(2):273-80. PubMed ID: 18067485
[TBL] [Abstract][Full Text] [Related]
3. Nephrogenic systemic fibrosis: a serious iatrogenic disease of renal failure patients.
Khurram M; Skov L; Rossen K; Thomsen HS; Marckmann P
Scand J Urol Nephrol; 2007; 41(6):565-6. PubMed ID: 17934986
[TBL] [Abstract][Full Text] [Related]
4. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
[TBL] [Abstract][Full Text] [Related]
5. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media.
Sieber MA; Pietsch H; Walter J; Haider W; Frenzel T; Weinmann HJ
Invest Radiol; 2008 Jan; 43(1):65-75. PubMed ID: 18097279
[TBL] [Abstract][Full Text] [Related]
6. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.
Marckmann P; Skov L; Rossen K; Dupont A; Damholt MB; Heaf JG; Thomsen HS
J Am Soc Nephrol; 2006 Sep; 17(9):2359-62. PubMed ID: 16885403
[TBL] [Abstract][Full Text] [Related]
7. Nephrogenic systemic fibrosis: center case review.
Lauenstein TC; Salman K; Morreira R; Tata S; Tudorascu D; Baramidze G; Singh-Parker S; Martin DR
J Magn Reson Imaging; 2007 Nov; 26(5):1198-203. PubMed ID: 17969162
[TBL] [Abstract][Full Text] [Related]
8. An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital.
Marckmann P
Eur J Radiol; 2008 May; 66(2):187-90. PubMed ID: 18328659
[TBL] [Abstract][Full Text] [Related]
9. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
Kallen AJ; Jhung MA; Cheng S; Hess T; Turabelidze G; Abramova L; Arduino M; Guarner J; Pollack B; Saab G; Patel PR
Am J Kidney Dis; 2008 Jun; 51(6):966-75. PubMed ID: 18501784
[TBL] [Abstract][Full Text] [Related]
10. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis.
Edward M; Quinn JA; Mukherjee S; Jensen MB; Jardine AG; Mark PB; Burden AD
J Pathol; 2008 Apr; 214(5):584-93. PubMed ID: 18220317
[TBL] [Abstract][Full Text] [Related]
11. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent.
Rydahl C; Thomsen HS; Marckmann P
Invest Radiol; 2008 Feb; 43(2):141-4. PubMed ID: 18197066
[TBL] [Abstract][Full Text] [Related]
12. Case-control study of gadodiamide-related nephrogenic systemic fibrosis.
Marckmann P; Skov L; Rossen K; Heaf JG; Thomsen HS
Nephrol Dial Transplant; 2007 Nov; 22(11):3174-8. PubMed ID: 17483196
[TBL] [Abstract][Full Text] [Related]
13. Extracellular Gd-CA: differences in prevalence of NSF.
Thomsen HS; Marckmann P
Eur J Radiol; 2008 May; 66(2):180-3. PubMed ID: 18342468
[TBL] [Abstract][Full Text] [Related]
14. Nephrogenic systemic fibrosis: risk factors and incidence estimation.
Sadowski EA; Bennett LK; Chan MR; Wentland AL; Garrett AL; Garrett RW; Djamali A
Radiology; 2007 Apr; 243(1):148-57. PubMed ID: 17267695
[TBL] [Abstract][Full Text] [Related]
15. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.
Broome DR
Eur J Radiol; 2008 May; 66(2):230-4. PubMed ID: 18372138
[TBL] [Abstract][Full Text] [Related]
16. [Nephrogenic systemic fibrosis].
Breitschaft A; Stahlmann R
Med Monatsschr Pharm; 2009 Oct; 32(10):377-82. PubMed ID: 19886227
[TBL] [Abstract][Full Text] [Related]
17. Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis.
Richmond H; Zwerner J; Kim Y; Fiorentino D
Arch Dermatol; 2007 Aug; 143(8):1025-30. PubMed ID: 17709661
[TBL] [Abstract][Full Text] [Related]
18. Nephrogenic systemic fibrosis: possible association with a predisposing infection.
Golding LP; Provenzale JM
AJR Am J Roentgenol; 2008 Apr; 190(4):1069-75. PubMed ID: 18356457
[TBL] [Abstract][Full Text] [Related]
19. A follow-up of four cases of nephrogenic systemic fibrosis: is gadolinium the specific trigger?
Singh M; Davenport A; Clatworthy I; Lewin J; Deroide F; Hubbard V; Rustin MH
Br J Dermatol; 2008 Jun; 158(6):1358-62. PubMed ID: 18363754
[TBL] [Abstract][Full Text] [Related]
20. Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: a single-center experience.
Lemy AA; del Marmol V; Kolivras A; High WA; Matos C; Laporte M; Nortier JL
J Am Acad Dermatol; 2010 Sep; 63(3):389-99. PubMed ID: 20619488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
